The Wistar Institute of Anatomy and Biology was founded in 1892 at its current site to operate as an independent research entity dedicated to the maintenance and enhancement of its anatomical collection and to """"""""the conduct of any other work for the increase of scientific knowledge."""""""" Over its history, The Wistar Institute has emerged as one of the nation's leading private basic research institutions. In recognition of its contributions in cancer research, the Institute received a Cancer Center Support (CCSG) and was designated by the National Cancer Institute (NCI) as a federally approved Cancer Center in 1972, specializing in basic research. In 1976 the NCI funded the addition of a Cancer Wing to the original Main Building. In 2002 Dr. Russel Kaufman was appointed Director and CEO of The Wistar Institute Cancer Center (Cancer Center). Following his arrival, Dr. Kaufman has led a restructuring of the Research Programs and an extensive review of the Shared Resources. Research at the Institute is organized into three programs: Gene Expression and Regulation; Cellular and Molecular Oncogenesis; and Immunology. Investigators are recognized for their leading contribution in gene regulation and chramatin modification, melanoma research, vaccine development, and translational research. The goals of the current CCSG application are to further expand on our success in these areas by recruiting new faculty to the Institute and by the Institute and by Providing an environment and resource to promote the success of the members of the Cancer Center. The Cancer Center will emphasize the study of macromolecular transcriptional complexs, mouse models of human cancer, organotypic model systems, antigen recognition and processing, immune cell trafficking, stem cell development, and systems biology. These areas of investigation will complement and expand existing areas of excellence and provide novel insights into the biology of cancer, as well as targets for cancer therapies.
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7 |
| Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228 |
| Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35 |
| Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269 |
| Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15 |
| Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426 |
| Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5: |
| Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS : |
Showing the most recent 10 out of 741 publications
